Identification of prostate cancer biomarkers in urinary exosomes
Supplementary Material Figures   Fig. S1 . Optimalization of exosomal protein amounts for mass spectrometry analysis. Increasing amounts of trypsinated exosomes were injected into a mass spectrometer to establish the minimal protein amount required for analysis. Number of unique peptides (A) and number of protein hits for 2 or more peptides, and 1 or more peptides (B) found at the corresponding exosomal protein amounts. The protein amount was measured using the BCA assay.
Fig. S2. Quantification analysis.
Increasing amounts of trypsinized exosome proteins were injected into an LTQ-Orbitrap XL and subjeced to lock mass quantification. A. Both total and individual quantification for two proteins (ezrin and tetraspanin-8) gave a linear response within the quantification range measured (R 2 = 0.987 (total), 0.9914 (ezrin), 0.9845 (tetraspanin-8). B. Quantitative values in ng (normalized to 100 ng) for total protein abundance as measured by iBAQ. iBAQ: Intensity-based absolute quantification.
3 Fig. S3 . Correlation studies of age, abundance and number of protein hits. Scatter plots investigating the correlation between total protein abundance (LFQ) and protein hits, age and total protein abundance (LFQ), and age and protein hits. Total protein abundance was measured as sum of TOP3TIC for all proteins identified in each sample.
Fig. S4. Comparison of proteins found in exosomes isolated from first and second morning urine voids.
The reproducibility of the three technical replicates was of 96.7%. Seven proteins were found exclusively in second urine (lactotransferrin (LTF), complement C4-B, sulfate transporter, protein AMBP, tetratricopeptide repeat protein 38, prolactin-inducible protein and fibrinogen alpha chain) and three proteins were found only in first urine (histidine triad nucleotide-binding protein 1, small prolinerich protein 2A, and serine/threonine-protein kinase PAK 2). Total urinary exosome is composed of proteins found in both control and patient protein samples. Proteins reduced by more than fivefold in patient samples are marked in red. SH3-binding proteins are emphasized.
6
Fig. S6. Biomarkers found in crude urine versus EPS urine.
This graph displays the prostate cancer to control ratio for the proteins found in our study that were suggested as prostate cancer markers in a recent review (Drake & Kislinger, 2014) . The proteins are sorted by p-value. Five proteins (ZA2G, FOLH1, PPAP, TRFL, KLK3) passed a threshold for Fisher Exact-test at p= 0.05. Three markers described in that review (GFD15, TIMP1, KLK11) were not consistently found in this study. Significantly up-or down-regulated in prostate cancer urinary exosomes (246 entries), iv) Up-or downregulated in prostate cancer (1586 entries).
8 Tables   Table S1 . Cohort description. The 16 patients undergoing robot-assisted laparoscopic radical prostatectomy due to prostate cancer (PAT) and the 15 healthy urine donors (CTR) are described. Gleason score and serum PSA is shown only for patients. Gleason score 7a and 7b correspond to 3+4 and 4+3 respectively. The pH and the presence of leukocytes, nitrites, proteins, glucose, ketones and blood were analyzed with a Combur 7 Strip-Test in an Urysis 1100 urine analyzer. Only samples with low (see Materials and Methods) or not detectable (n.d.) levels of leukocytes, nitrites, proteins, glucose, ketones or blood were included in the cohort. Table S2 . List of proteins significantly changed in urinary exosomes from prostate cancer patients in alphabetical order. Full annotation of the 246 enriched proteins with Gene Name, Alternative Gene Names, Uniprot Entry Name, Uniprot Accession Number and Full Protein Name, sorted alphabetically by latter. Table S4 . Heat-map for the prostate biomarkers candidates in urinary exosomes at 100% specificity. The heat-map displays all proteins that are significantly changed. Red/grey marker describes presence/absence of a specific protein above a threshold (LFQ-based) set to reach 100% specificity. Proteins that were confidently detected in patient samples only are indicated with blue, proteins significantly down-regulated in yellow. The table is sorted according to sensitivity (high-low). Table S5 . Heat-map for the prostate biomarkers candidates in urinary exosomes at maximum combined sensitivity and specificity. The heat-map contains proteins that are significantly changed at 100% specificity. Red/grey marker describes presence/absence of a specific protein above a threshold (LFQ-based) set to reach maximum combined sensitivity and specificity based on Youden's J analysis. Yellow colour show down-regulated proteins as measured by quantitative analysis, blue colour show proteins only present in patient urinary exosomes in discovery analysis. The table is sorted according to combined sensitivity and specificity (high-low). 
